Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Beyfortus
Pharma
Sanofi isn't sweating a potential RSV showdown with Merck
Despite Merck & Co. homing in on approval for its infant RSV antibody clesrovimab, Sanofi thinks Beyfortus can hold its own.
Fraiser Kansteiner
Oct 25, 2024 11:12am
Sanofi, AZ look to avoid Beyfortus shortfalls this year
Sep 17, 2024 11:33am
Sanofi sticks to its guns on Beyfortus' blockbuster potential
Jul 25, 2024 10:13am
Sobi boosts hematology sales with growth across key brands
Jul 16, 2024 1:27pm
Sanofi is going all in on Dupixent's next potential nod in COPD
Apr 25, 2024 12:37pm
Pfizer plots new RSV filing with positive Abrysvo data in adults
Apr 9, 2024 6:45am
